Preliminary data of familial hypercholesterolemia (FH) patients in Romania


      • We have enrolled 59 patients (0.7%) who had a FH score above 3.
      • The mean LDL-c level upon enrollment was 229.84 mg/dl for the untreated patients.
      • 91.52% of the patients had a possible FH score, while 6.7% a probable FH score and 1.6% had a definite FH score.
      • Based on this data the prevalence of FH in Romania is: 1:213.


      Background and aims

      Familial hypercholesterolemia (FH) is one of the most frequent monogenic cholesterol disorders. Its prevalence varies in adults between 1/500–1/217 individuals in the heterozygous form. The objective of this study was to uncover the FH prevalence in Romania to perform an adequate prevention for high risk individuals.


      We have conducted an epidemiological study between January 2015 and January 2018 by recruiting patients from the CardioPrevent Foundation based on their FH score (taking into account their low density lipoprotein cholesterol (LDLc) levels, clinical characteristics such as premature coronary artery disease (CAD), and their family history of premature cardiovascular disease). We have calculated the probability of FH using the Dutch Lipid Clinic Network (DLCN) criteria and we have included patients with a score over 3 points.


      We have enrolled 59 patients, out of whom 61% were females. 8.4% of the patients recruited had a first degree relative with premature coronary artery disease and 5% had a relative with LDLc >190 mg/dl (without statin treatment). 10.16% of the patients had coronary artery disease and 15.25% peripheral vascular disease. 91.52% of the patients had a possible FH, while 6.7% had a probable FH and 1.6% a definite FH diagnosis. Based on this data, the prevalence of FH in Romania is: 1:213.


      To raise the suspicion for FH is easy at the level of the general practitioners, based on the analysis of LDLc levels and premature CAD occurrence. Diagnosis can be further refined using an available online free software.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        For the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013; 34 (3478–34902.2)
      1. Risk of fatal coronary heart disease in familial hypercholesterolaemia.
        Scientific Steering Committee on behalf of the Simon Broome Register Group BMJ. 1991; 303: 893
        • Perak A.M.
        • Ning H.
        • de Ferranti S.D.
        • et al.
        Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype.
        Circulation. 2016; 134: 9-19
        • Sharifi M.
        • Higginson E.
        • Bos S.
        • et al.
        Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
        Atherosclerosis. 2017; 263: 405-411
        • Benn M.
        • Watts G.F.
        • Tybjærg-Hansen A.
        • et al.
        Mutations causative of familial hypercholesterolaemia: screening of 98.098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.
        Eur. Heart J. 2016; 37: 1384-1394
        • Neil A.
        • Cooper J.
        • Betteridge J.
        • et al.
        On behalf of the Simon Broome Familial Hyperlipidaemia Register Group, Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
        Eur. Heart J. 2008; 29: 2625-2633
        • Watts G.F.
        • Gidding S.
        • Wierzbickid A.S.
        • et al.
        Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.
        Int. J. Cardiol. 2014; 171: 309-325
        • Austin M.A.
        • Hutter C.M.
        • Zimmern R.L.
        • et al.
        Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.
        AJE (Am. J. Epidemiol.). 2004; 160: 407-420
        • de Ferranti S.D.
        • Rodday A.M.
        • Mendelson M.M.
        • et al.
        Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES).
        Circulation. 2016; 133: 1067-1072
      2. EAS Familial Hypercholesterolaemia Studies Collaboration Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.
        Atherosclerosis Suppl. 2016; : 1-32
        • World Health Organization
        Familial Hypercholesterolemia—report of a Second WHO Consultation.
        World Health Organization, Geneva, Switzerland1999 ((WHO publication no. WHO/HGN/FH/CONS/99.2)
        • Fahed A.C.
        • Nemer G.M.
        Familial hypercholesterolemia: the lipids or the genes?.
        Nutr. Metab. 2011; 8: 23
        • Mota M.
        • Popa S.G.
        • Mota E.
        Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study.
        J. Diabetes. 2016; : 336-344
        • De Backer G.
        • Besseling J.
        • Chapman J.
        • et al.
        Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
        Atherosclerosis. 2015; 241: 169-175
        • Dumitrescu A.
        • Mosteoru S.
        • Gaita D.
        • et al.
        The prevalence of familial hypercholesterolemia in children from Timisoara.
        Atherosclerosis. 2017; 263: e170-e171
        • Goldberg A.C.
        • Hopkins P.N.
        • Toth P.P.
        • et al.
        Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients, clinical guidance from the national lipid association expert panel on familial hypercholesterolemia.
        J. Clin. Lipidol. 2011; 5: S1-S8
        • Khera A.V.
        • Won H.-H.
        • Peloso G.M.
        • et al.
        Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
        J. Am. Coll. Cardiol. 2016; 67: 2578-2589